(NORML) Pulmonary complications associated with the regular smoking of cannabis are “relatively small” and far lower than those associated with tobacco smoking, according to a recent review published in the June edition of the scientific journal Annals of the American Thoracic Society.
The paper – authored by Donald P. Tashkin, MD, emeritus professor of medicine and medical director of the Pulmonary Function Laboratory at the David Geffen School of Medicine at University of California, Los Angeles – is “the most comprehensive and authoritative review of the subject ever published,” according to an accompanying commentary. Donald Tashkin conducted US-government sponsored studies of marijuana and lung function for over 30 years.
His review finds that although smoking cannabis may be associated with symptoms of chronic bronchitis, studies do not substantiate claims that it is positively associated with the development of lung cancer, chronic obstructive pulmonary disease (COPD), emphysema, or bullous lung disease.
“[H]abitual use of marijuana alone does not appear to lead to significant abnormalities in lung function,” Tashkin writes. “[F]indings from a limited number of well-designed epidemiological studies do not suggest an increased risk of either lung or upper airway cancer from light or moderate use. … Overall, the risks of pulmonary complications of regular use of marijuana appear to be relatively small and far lower than those of tobacco smoking.”